Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit

Circulation

Volumn 106, Issue 23, 2002, Pages 2955-2960

  Rashid, Shirya ^a   Uffelman, Kristine D ^a   Barrett, P Hugh R ^a,b   Lewis, Gary F ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Apolipoproteins; Atorvastatin; Hypercholesterolemia; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN; IODINE 131;

ARTICLE; CATABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; HUMAN; ISOTOPE LABELING; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOACTIVITY;

ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL; CHOLESTEROL ESTERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IODINE RADIOISOTOPES; LIPOPROTEINS, HDL; MALE; METABOLIC CLEARANCE RATE; MODELS, ANIMAL; PHOSPHOLIPIDS; PYRROLES; RABBITS; RADIOACTIVE TRACERS; TRIGLYCERIDES;

EID: 0037016055     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000038303.84249.4A     Document Type: Article

References (35)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hyperchotesterolemia. N Engl J Med. 1995;333:1301-1307.
2. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol 1998;81:582-587.
4. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.
5. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol. 2001;11:627-637.
6. Roeters van Lennep JE, Westerveld HT, Roeters van Lennep HWO, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000;20:2408-2413.
7. Crouse JR III, Frohlich J, Ose L, et al. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 1999;83:1476-1477.
8. Kastelein JJP, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000;86:221-223.
9. Illingworth DR, Crouse JR III, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001;17:43-50.
10. Ma P, Hegele RA, Yale JF, et al. CAVEAT: A randomised, double-blind, parallel group evaluation of cerivastatin 0.4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type IIb) dyslipidaemia. Br J Cardiol. 2000;7:780-786.
11. Wierzbicki AS, Lumb PJ, Semra Y, et al. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM. 1999;92:387-394.
12. Wierzbicki AS, Lumb PJ, Chik G, et al. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol. 2000;86:547-549, A9.
13. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268-275.
14. Rashid S, Uffelman K, Barrett PHR, et al. Triglyceride enrichment of HDL does not alter HDL selective cholesteryl ester clearance in rabbits. J Lipid Res. 2001;42:265-271.
15. Auerbach BJ, Krause BR, Bisgaier CL, et al. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: Atorvastatin versus lovastatin. Atherosclerosis. 1995;115:173-180.
16. Lamarche B, Uffelman KD, Steiner G, et al. Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoproteins in a rabbit model. J Lipid Res. 1998;39:1162-1172.
17. Cheung MC, Albers JJ. The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay. J Clin Invest. 1977;60:43-50.
18. Brousseau ME, Santamarina-Fojo S, Zech LA, et al. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits: In vivo apolipoprotein A-I catabolism is delayed in a gene dosedependent manner. J Clin Invest. 1996;97:1844-1851.
19. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: The DALI study: A double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001;24:1335-1341.
20. Marais AD, Firth JC, Bateman ME, et al. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:1527-1531.
21. Nieuw Amerongen GP, Vermeer MA, Negre-Aminou P, et al. Simvastatin improves disturbed endothelial barrier function. Circulation. 2000;102:2803-2809.
22. Alegret M, Verd JC, Diaz C, et al. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur J Pharmacol. 1998;347:283-291.
23. Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: Triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis. 1995;117:237-244.
24. Schaefer JR, Schweer H, Ikewaki K, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis. 1999;144:177-184.
25. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432.
26. Bonn V, Cheung RC, Chen B, et al. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apoliprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002;163:59-68.
27. Hamilton JA, Vural JM, Carpentier YA, et al. Incorporation of medium chain triacylglycerols into phospholipid bilayers: Effect of long chain triacylglycerols, cholesterol, and cholesteryl esters. J Lipid Res. 1996;37:773-782.
28. Quig DW, Zilversmit DB. High density lipoprotein metabolism in a rabbit model of hyperalphalipoproteinemia. Atherosclerosis. 1989;76:9-19.
29. Hailer S, Wolfram G, Zollner N. Changes in serum lipoproteins in humans following the infusion of a fat emulsion containing medium- and long-chain triglycerides. Eur J Clin Invest. 1987;17:402-407.
30. Le NA, Innis-Whitehouse W, Li X, et al. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin. Metabolism. 2000;49:167-177.
31. Guerin M, Lassel TS, Le Goff W, et al. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20:189-204.
32. Lamarche B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999;103:1191-1199.
33. Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res. 1999;40:187-201.
34. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA. 2001;285:1711-1718.
35. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70-76.